The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cobra Therapy for Rheumatoid Arthritis

Cobra Therapy for Rheumatoid Arthritis

June 1, 2010 • By Lilian H.D. van Tuyl, PhD, and Maarten Boers, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

At present, there are many different ways to treat rheumatoid arthritis (RA), raising questions about which approaches produce the best results in the real-world setting and which are the most cost effective. Among these approaches, COBRA (based on the Dutch acronym Combinatie therapie Bij Rheumatoide Arthritis) therapy is a well-known and thoroughly investigated combination therapy for the treatment of early RA. This combination consists of three disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, and an initial period with a high dose of prednisolone (60 mg/d tapered in six weeks to 7.5 mg/d). (See Figure 1, p. 23.) COBRA leads to faster suppression of disease activity and less joint damage in the long term compared with sulfasalazine monotherapy. Moreover, the COBRA combination is as effective as high-dose methotrexate in combination with infliximab and is cost effective compared with other antirheumatic therapies.1-5

You Might Also Like
  • New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal
  • ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?
  • 4 Rheumatoid Arthritis Therapy Principles, & New Drug Info
Explore This Issue
June 2010

Despite these features and its long-term benefits, COBRA therapy is not often prescribed in clinical practice, at least not by Dutch rheumatologists. We therefore asked, “Why not?” and performed studies to better understand the prescription pattern of COBRA and determine whether it can be changed. For our study, we sent a small questionnaire to every rheumatologist in the Netherlands to measure attitudes towards the combination therapy and the frequency of use.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

From the responses, we learned that COBRA therapy was regarded as effective and safe but also rather complicated to administer. Remarkably, although the overall attitude of rheumatologists towards COBRA therapy was slightly positive, the majority of responding rheumatologists did not intend to prescribe COBRA therapy in the near future. These results gave us the first indication of the contradictory feelings surrounding COBRA therapy.6

To study this discrepancy further, we organized focus group discussions with both patients and rheumatologists (in separate groups). In these groups, rheumatologists indicated that they were positive about the effectiveness of COBRA therapy but concerned about their patients’ possible negative reaction to the large number of pills to be taken. Doctors feared the reaction of patients, including a sense of failure toward their providers and that the therapy prescribed is considered disagreeable. In addition, rheumatologists felt that they lacked the time to explain and prescribe COBRA therapy and felt uncomfortable prescribing high doses of prednisolone.7

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

On the other hand, patients who joined the focus groups (mostly late RA patients with a broad experience of treatment regimens, including COBRA) were positive about an aggressive combination therapy such as COBRA therapy. Importantly, patients said that they had no qualms taking many pills if this would provide immediate relief of their symptoms or might improve their prognosis. Patients associated prednisolone with negative side effects (especially their effects on appearance), but they were also aware of its benefits and the need to take prednisolone in rough times of active arthritis. Patients stated that they based their opinions on their own experience at the start of the disease and concluded that taking many pills felt much better than the pain and limitations they were facing with the disease. A decrease in the number of pills after a period of intensive treatment was highly appreciated.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Cobra Therapy, disease-modifying antirheumatic drug, DMARD, prednisolone, Rheumatoid arthritis, TreatmentIssue: June 2010

You Might Also Like:
  • New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal
  • ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?
  • 4 Rheumatoid Arthritis Therapy Principles, & New Drug Info
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.